The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
Theodora A. Constantin, Anabel Varela‐Carver, Kyle K. Greenland, Gilberto Serrano de Almeida, Ellen Olden, Lucy Penfold, Simon Ang, Alice Ormrod, Damien A. Leach, Chun‐Fui Lai, Edward Ainscow, Ash K. Bahl, David Carling, Matthew John Fuchter, Simak Ali, Charlotte Lynne Bevan
This study investigates the antitumour activity of CT7001, a CDK7 inhibitor, in castration-resistant prostate cancer models, showing it inhibits proliferation and enhances enzalutamide efficacy.
British Journal of Cancer · Apr 19, 2023Peer-reviewedMolecular Biology